Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Nivolumab + Ipilimumab + Cabozantinib for Melanoma
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing a combination of three drugs to treat melanoma. The drugs will be given for 12 weeks, followed by maintenance therapy for up to 2 years. The goal is to see how well the combination works in preventing disease progression.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service